Evidence map›Paper›PMID 28443575›Full record

ArticleBalkan medical journal2017

The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study.

Salih Kılıç, Ahmet Çelik, Hüseyin Altuğ Çakmak, Abdülmecit Afşin, Ahmet İlker Tekkeşin, Gönül Açıksarı, Mehmet Erdem Memetoğlu, Fatma Özpamuk Karadeniz, Ekrem Şahan, Mehmet Hayri Alıcı and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Balkan medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 1 country.

Salih KılıçDepartment of Cardiology, Ege University School of Medicine, İzmir, Turkey.
Ahmet ÇelikDepartment of Cardiology, Mersin University School of Medicine, Mersin, Turkey.
Hüseyin Altuğ ÇakmakClinic of Cardiology, Kaçkar State Hospital, Rize, Turkey.
Abdülmecit AfşinDepartment of Cardiology, İnönü University School of Medicine, Malatya, Turkey.
Ahmet İlker TekkeşinClinic of Cardiology, Siyami Ersek Training and Research Hospital, İstanbul, Turkey.
Gönül AçıksarıClinic of Cardiology, İstinye State Hospital, İstanbul, Turkey.
Mehmet Erdem MemetoğluClinic of Cardiovascular Surgery, Siyami Ersek Training and Research Hospital, İstanbul, Turkey.
Fatma Özpamuk KaradenizClinic of Cardiology, Balıklıgöl State Hospital, Şanlıurfa, Turkey.
Ekrem ŞahanClinic of Cardiology, Atatürk Chest Disease and Chest Surgery Training and Research Hospital, Ankara, Turkey.
Mehmet Hayri AlıcıClinic of Cardiology, 25 Aralık State Hospital, Gaziantep, Turkey.
Yüksel DereliDepartment of Cardiovascular Surgery, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey.
Ümit Yaşar SinanDepartment of Cardiology, İstanbul University Institute of Cardiology, İstanbul, Turkey.
Mehdi ZoghiDepartment of Cardiology, Ege University School of Medicine, İzmir, Turkey.
Dr. Siyami Ersek Göğüs Kalp Ve Damar Cerrahisi Eğitim Ve Araştırma Hastanesi · TREge University · TRAnkara Spine Center · TRBalikli Rum Vakfi Hastanesi · TRInonu University · TRIstanbul University · TRIstinye University · TRMersin Üniversitesi · TRNecmettin Erbakan University · TRSivas State Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe time in therapeutic range values may vary between different geographical regions of Turkey in patients vitamin K antagonist therapy.

aimsTo evaluate the time in therapeutic range percentages, efficacy, safety and awareness of warfarin according to the different geographical regions in patients who participated in the WARFARIN-TR study (The Awareness, Efficacy, Safety and Time in Therapeutic Range of Warfarin in the Turkish population) in Turkey. STUDY

designCross-sectional study.

methodsThe WARFARIN-TR study includes 4987 patients using warfarin and involved regular international normalized ratio monitoring between January 1, 2014 and December 31, 2014. Patients attended follow-ups for 12 months. The sample size calculations were analysed according to the density of the regional population and according to Turkish Statistical Institute data. The time in therapeutic range was calculated according to F.R. Roosendaal's algorithm. Awareness was evaluated based on the patients' knowledge of the effect of warfarin and food-drug interactions with simple questions developed based on a literature review.

resultsThe Turkey-wide time in therapeutic range was reported as 49.5%±22.9 in the WARFARIN-TR study. There were statistically significant differences between regions in terms of time in therapeutic range (p>0.001). The highest rate was reported in the Marmara region (54.99%±20.91) and the lowest was in the South-eastern Anatolia region (41.95±24.15) (p>0.001). Bleeding events were most frequently seen in Eastern Anatolia (41.6%), with major bleeding in the Aegean region (5.11%) and South-eastern Anatolia (5.36%). There were statistically significant differences between the regions in terms of awareness (p>0.001).

conclusionStatistically significant differences were observed in terms of the efficacy, safety and awareness of warfarin therapy according to different geographical regions in Turkey.

Indexed as

Geographic MappingTime FactorsAgedAnticoagulantsCross-Sectional StudiesDrug MonitoringFemaleHemorrhageHumansInternational Normalized RatioMaleMiddle AgedTurkeyWarfarinAnticoagulantsWarfarinawareness geographical differences.Warfarin

Identifiers

PMID28443575
PMCPMC5615968
OpenAlexW2592009663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.